PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
61.53%
Cash & equivalents growing 61.53% while AXSM's declined -13.36%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
61.53%
Below half of AXSM's -13.36%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
59.75%
≥ 1.5x AXSM's 19.75%. David Dodd might see a short-term liquidity advantage or potential underutilized capital.
529.47%
Below half AXSM's -7.48%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
588.21%
Below half of AXSM's 4325.81%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
63.35%
0.5-0.75x AXSM's 103.88%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
9.62%
Less than half of AXSM's 54.27%. David Dodd sees a more disciplined AP approach or lower volume.
59.49%
Higher Short-Term Debt Growth compared to AXSM's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
103.88%
Higher Deferred Revenue (Current) Growth compared to AXSM's zero value, indicating better performance.
-531.94%
Higher Other Current Liabilities Growth compared to AXSM's zero value, indicating worse performance.
9.77%
Less than half of AXSM's 73.41%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1866750.00%
Above 1.5x AXSM's 149.00%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
661.90%
Above 1.5x AXSM's 123.88%. Michael Burry sees a potential leverage warning sign.
13.64%
Above 1.5x AXSM's 2.65%. Michael Burry suspects heavy new equity expansion or dilution.
-2.98%
Below half AXSM's -9.23%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.57%
≥ 1.5x AXSM's 3.41%. David Dodd sees stronger capital base growth than competitor.
63.35%
0.5-0.75x AXSM's 103.88%. Martin Whitman sees underexpansion or possible missed opportunities.
No Data
No Data available this quarter, please select a different quarter.
1244.16%
Above 1.5x AXSM's 87.29%. Michael Burry sees a major jump. Investigate leverage rationale.
-58.28%
Less than half of AXSM's 160.34%. David Dodd sees better deleveraging or stronger cash buildup than competitor.